Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any idea if CRXM responded to the order?
They have let the website sevices go to shit. Not that they would have posted the info anyway. That would show at least some responsibility on their part to keep investors informed.
https://genebiotherapeutics.com/press/
https://genebiotherapeutics.com/investors/
Good to hear.....Thanks for your efforts in reaching out......Generx is valuable since its at a Phase 3 Fast Track status!!.....Hopefully a real deal is pending!!!!!!
Chris is alive , he said he’s working on buying the company back from Nostrum. Praying he is successful .
Good question. Most likely answer is money. I'm sure it's going to take hundreds of thousands to get current.
If Nostrum isn't able to provide financial support then what good are they? My expectattion was they could fund the trial directly or had resources to get the financing. Perhaps no lender will work with them given their situation. Enough time has passed I'd hoped Chris would have found a way to move things along without Nostrum.
No one seems to know anything based on the lack of comments.
just wondering maybe company not active anymore ????
Ok, just clarifying. Seems like a running back situation.
Yes, .10 a share. I am hedging my bet in case they actually bring this thing back to life. If you are making a serious offer, you must have reason to believe it will come back. They have never responded to my emails so I am completely blind but you may not be.
So you want 2x what most paid (.05) for shares in a company you think is dead? Or did you mean .01?
I can't respond privately so will do it here. Absolutely, I would be interested in selling my shares to you. I am going to give them time to respond to the SEC complaint before selling. If it looks like Reinhard will let it die on the vine, as someone else suggested, then you can have all of my 800,000 shares for .10 a share. Subject to change, of course.
Of course, if I could!
Jan 29 2024.....Altitrade Posted......"Still confident that things will eventually come together".....I wonder what they think of this new SEC notice?
I did.
No reply yet.
Anyone reached out to CRXM management about this?
So you’d sell your shares?
That has been my hope for years but at this point, I seriously doubt there is any value here. If I remember correctly, this thing was fast tracked for phase 3 testing almost 20 years ago and Reinhard has been unable to even start it. If there was any value here, someone would have found it by now.
Thanks for posting. Let's see if they respond to the order or let this thing die in the vine.
There is still valuable IP here, so maybe some other biopharma sees potential and takes it over.
CRXM: SEC Admin. Proceeding for severely delinquent Financials:
https://www.sec.gov/files/litigation/admin/2024/34-99675.pdf
Another month has gone by with nothing from the company. Silence sucks.
I wonder why they just can’t get current so this can trade . If they need money to fund Phase 3 , get current , Raise the OS and sell shares . If I could get out at .01 I would be stoked.
I wonder what the current situation with Nostrum is with their interest and financial means to move things forward.
Altitrade thanks.....Good to hear!
Still confident that things will eventually come together and CRXM will begin trading again. In for the long haul.
Three months ago this was his position. I am curious if anything has changed:
Altitrade Partners
Re: bentleyt post# 6073
Tuesday, October 24, 2023 10:27:41 AM
Post#
6074
of 6111
What makes you feel so confident?
- A strong belief in GeneRx drug therapy and CEO Chris Reinhard's ability to get it to the market.
What do you honestly see for the future of CRXM
- Sorry, our crystal ball is currently in the shop for repair.
What is your anticipated timeframe?
- As long as it takes
Altitrade......Any thoughts where CRXM is headed
I'm kind of curious myself.
My take on CR is he's a pretty bright guy and means well. I question whether he has the skillset to raise funds at this point to move research forward. Clearly he put all of his, and our eggs in the Nostrum basket. Now that Nostrum is in a bad way, what is the work around?
One would think Mr Grainer would have the know how and contacts to make this happen but here we sit almost three years since the last meaningful news release and nearly 2 years since the last filing.
_fatty_, When you refer to him as a clown, are you implying it solely based on his makeup and large shoes? I'm inclined to think that's not your actual point. Could you elaborate on any specific actions of the CEO that substantiate your claim?
Makeup and the oversized shoes
What makes a clown, a clown?
_fatty_, I humbly present to you the question "What makes this CEO a clown?" I assure you is borne out of genuine interest. Your answer to this question may benefit this board readers and myself.
Yep, both replies to my posts. Isn’t that coincidence and not weird at all. If I had to guess who went ahead and created a second account just to respond to my posts, I could probably guess on the first try.
You should be welcoming that Acct to IHUB. Fresh one with only 2 post.
Welcome to the board. Best of luck to you.
_fatty_, What makes this CEO a clown?
Nobody gives a $hit about shareholders. I'll hold all my worthless shares till end of 2024...then if nothing. BIG TAX write off.
Some say the key is not to lose big....well, $hit happens. We take risks - that's life.
The thing that bothers me is Nostrum has been under financial pressure for going on a couple years now. If they had helped with the funding early on we would be at the end of the trial by now and potentially have a big pharma partner or have been bought out. This would have put Nostrum in a much stronger financial position as well as shareholders.
I have no doubt Chris Reinhard has known about these issues for quite some time and nothing has changed. As far as I know he has not publicly communicated with shareholders in a very long time. I know several have reached out with little or no success.
For Pete's sake, our COB/CFO is Nostrum's CFO (as far as I know). How can this not be handled more optimally given such tight control?
A New Year is here. Nostrum knows their punishment from the Feds. It is time for them to figure out the plan AND inform CRXM shareholders.
docj.....What you found is the reason why CRXM has stalled out.....We need a solid Pharma company to buy out Nostrum's CRXM ownership position and get rid of them forever.....Thanks for your Due Diligence
I'm not sure Nostrum Pharma or Nostrum Lab exists anymore. Website links do not work for me. Could be they are rebranding I suppose. Either way Gene Bio is probably low on their to do list funding wise.
You may be correct about Gene Bio's ability to move things ahead. That was the whole idea about bringing in the pharma group. But I doubt Chris Reinhard expected Nostrum to have this happen which I just found using Google:
https://www.justice.gov/opa/pr/drugmaker-nostrum-and-its-ceo-agree-pay-50-million-settle-false-claims-act-claims
Generx Is Still A Phase 3 Fast Tracked Heart Drug That Works.....The CEO Told Me A Year Or So Ago That Generx Is 10 Years Ahead Of Any Competition....Generx Was Featured On The Cover Of Scientific American In 2017 For A Reason.....CRXM Could Easily Be Brought Out By A Top Biotech Looking For A Late Stage Drug Prospect.....IMHO This Could Turn On A Dime And Become A Winner For Shareholders.....Sure This Investment Has Been A Nightmare So Far But Hope Still Prevails!
And so far, very wrong. Their opinion is usually couched in vague optimism but it is obvious to me, this turkey is done. They were fast tracked for phase 3 many years ago and have done squat, not to mention they have been dark for 2 or 3 years. I am pretty sure this will go down as a losing pick for Altitrade.
However, they will be the first to say "win some, lose some".
docj......Maybe Altitrade Can Offer Their Advice.....They Are Very Knowledgable Regarding CRXM
Anyone have experience in being an activist investor and getting put on the BOD of a public company to help a company move ahead?
I know we have a couple 5% +/- shareholders. Perhaps one might be interested in being our Carl Icahn or Bill Ackman.
CEO is a clown. SEC is a joke. They pick and choose specific targets to go after. Useless. Don’t expect much from either.
Hope you had a good year and you can just write this loss off and move on
𝐁𝐑𝐄𝐀𝐊𝐈𝐍𝐆 🚨 𝗨𝗡𝗣𝗥𝗘𝗖𝗘𝗗𝗘𝗡𝗧𝗘𝗗 𝗖𝗢𝗡𝗚𝗥𝗘𝗦𝗦𝗜𝗢𝗡𝗔𝗟 𝗢𝗣𝗘𝗡 𝗟𝗘𝗧𝗧𝗘𝗥 𝗧𝗢𝗪𝗔𝗥𝗗𝗦 𝗧𝗛𝗘 𝗨.𝗦. 𝗥𝗘𝗚𝗨𝗟𝗔𝗧𝗢𝗥𝗦 𝗗𝗘𝗠𝗔𝗡𝗗𝗜𝗡𝗚 𝗧𝗥𝗔𝗡𝗦𝗣𝗔𝗥𝗘𝗡𝗖𝗬 𝗙𝗢𝗥 𝗥𝗘𝗧𝗔𝗜𝗟 𝗜𝗡𝗩𝗘𝗦𝗧𝗢𝗥𝗦 $MMTLP @FINRA @SECGov @GaryGensler
— Meta News🚨 (@MMATNEWS) December 22, 2023
🚨LIVE🚨 with… pic.twitter.com/1nP79twB8D
Neither the CEO, the COB nor the SEC are willing to comment on whether Sabby/Mintz were shorting CRXM. I've asked.
I remember Sabby was here:
“A recent one that’s received a good deal of attention involves Hal D. Mintz and his firm, Sabby Management LLC, which managed two private funds. Sabby mismarked tickets for short sales, saying they were long sales. By selling without borrowing stock, the firm was unable to make delivery. In addition:
The SEC’s complaint further alleges that Sabby Management and Mintz tried to conceal their fraudulent trading, including by using securities acquired after the trades to make it appear to brokers executing the trades that they had complied with the requirement to have borrowed or located the shares prior to their trades. As the complaint alleges, when questioned by at least one broker regarding their trading, Sabby Management and Mintz repeatedly lied about the trading.”
https://www.securitieslawyer101.com/2023/what-short-selling-is-and-isnt/
I’ll hold these until I croak, but it would be really cool to see this company come out of nowhere and surprise everyone.
Not holding my breath though.
Year coming to an end. Hope y'all had a great year to write off this trash
Yes All The Best And Hopefully We See A Big Turnaround For CRXM
Blessings to everyone. CRXM investment aside, I have lots to be thankful for. Take care and enjoy the holiday.
On August 2, 2021, the Audit Committee approved the appointment of RAM Associates, LLP (“RAM Associates”) as our new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal years ending December 31, 2021 and 2020. RAM Associates has served as the auditor for Nostrum Laboratories, Inc. and its affiliates, which are subsidiaries of Nostrum Pharmaceuticals LLC, our largest shareholder, since 2008.
Clinicaltrials.com update:
https://clinicaltrials.gov/ct2/show/NCT02928094?term=generx&rank=1
Understanding refractory angina and the AFFIRM study:
https://www.myrefractoryangina.com/
Taxus Cardium Announces Name Change To Gene Biotherapeutics
January 10, 2018 PR-M01-18-NI-021
SAN DIEGO, Jan. 8, 2018 /PRNewswire/— Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Gene Biotherapeutics Inc.
The name change reflects the Company's plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs. Gene Biotherapeutics is actively pursuing the acquisition of clinical development and commercialization rights to new and innovative, late-stage, DNA-based product opportunities focused on multiple forms of cancer to leverage the company's established and validated adenovector-based technology platform and deep experience in the clinical advancement and commercialization of gene therapy product candidates.
Previously, the Company established Angionetics Inc., an 85% majority-owned subsidiary, to lead Gene Biotherapeutics' cardiovascular clinical research and commercialization activities. Angionetics is currently focused on independent financings to support advancement of the FDA-cleared, Generx AFFIRM Phase 3 clinical study of patients with refractory angina (myocardial ischemia) due to advanced coronary artery disease. There are an estimated 1.0 million patients with refractory angina in the United States. Gene Biotherapeutics' plan to advance forward to establish Angionetics as an independent company remains unchanged. As previously reported, Gene Biotherapeutics expects to retain a substantial long-term equity investment in Angionetics following completion of the planned external financings. For more information about the Generx AFFIRM Phase 3 clinical study visit www.MyRefractoryAngina.com.
Angionetics is also considering the initiation of multiple Phase 2 clinical studies to evaluate the Generx angiogenic gene therapy product candidate as a treatment for patients with Cardiac Syndrome X (microvascular dysfunction) and certain forms of congestive heart failure, including ischemic cardiomyopathy.
Angionetics' Generx [Ad5FGF-4] is a first in class, disease altering, one-time administered, late-stage, angiogenic gene therapy product candidate which has been biologically engineered to enhance blood flow (perfusion) in ischemic regions of the heart by leveraging cardiac plasticity to promote the natural formation and growth of microvascular coronary structures (collateral vessels). This is achieved by stimulating and augmenting the heart's innate natural capacity to modulate the enlargement of pre-existing collateral arterioles (arteriogenesis), and to form new capillary vessels (angiogenesis) in select ischemic regions downstream from large coronary arteries.
Angionetics is being uniquely positioned to become a leading molecular interventional cardiology company, and is seeking to develop a portfolio of new and innovative, single-treatment, gene-based, catheter-administered therapeutic products focused on the biologic modulation of cardiac conductivity, contraction and angiogenic revascularization to address the global unmet medical needs of millions of patients with multiple forms of heart disease. Consistent with Angionetics' business strategy, the company is currently considering the acquisition of several early-stage gene therapy product candidates. To learn more about Angionetics visit www.angionetics.com.
As previously reported, Gene Biotherapeutics further plans to monetize its FDA-cleared, U.S.-patented, Excellagen, a highly-purified, aseptically-manufactured, fibrillar bovine collagen [2.6%] flowable dermal matrix for the treatment of diabetic neuropathic lower extremity ulcers, pressure and venous ulcers as well as other wound healing applications. Excellagen has demonstrated its medical utility as a delivery platform for stem cells, and also carries the potential as a topical dermal delivery vehicle for small molecule drugs, peptides, proteins, and exosomes. Excellagen® has been designated as a skin substitute (bearing a unique product Q Code), in accordance with the standards established by the U.S. Centers for Medicare and Medicaid Services (CMS). For more information about Excellagen, visit https://www.youtube.com/watch?v=D2GYCYc_8JE.
As of December 31, 2017, approximately 14.3 million shares of Gene Biotherapeutics Common Stock were issued and outstanding, and approximately 4.6 million additional shares of Common Stock have been reserved for future issuance upon the conversion of the Series A Convertible Preferred Stock.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |